KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses[2].IC50 & Target: EphA4 receptorIn Vitro: KYL peptide blocks the extracellular ligand-binding domain of EphA4, abolishes the Aβ-stimulated EphA4 tyrosine phosphorylation[2].
KYL peptide abolishes the Aβ-triggered reduction of dendritic spines in cultured hippocampal neurons[2].